Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2012 Financial Results on November 7, 2012

  Seattle Genetics to Host Conference Call and Webcast Discussion of Third
  Quarter 2012 Financial Results on November 7, 2012

Business Wire

BOTHELL, Wash. -- October 24, 2012

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its
third quarter and year-to-date 2012 financial results on Wednesday, November
7, 2012, after the close of financial markets. Following the announcement,
company management will host a conference call and webcast discussion of the
results and provide a general corporate update. Access to the event can be
obtained as follows:

LIVE access on Wednesday, November 7, 2012
1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

  *Telephone (866) 225-8754 (domestic) or (480) 629-9866 (international);
    conference ID 4570300
  *Webcast available at http://www.seattlegenetics.com/ in the Investors and
    News section

REPLAY access

  *Telephone replay will be available beginning at approximately 3:30 p.m. PT
    on Wednesday, November 7, 2012, through 5:00 p.m. PT on Friday, November
    9, 2012, by calling (800) 406-7325 (domestic) or (303) 590-3030
    (international); conference ID 4570300
  *Webcast replay will be available on the Seattle Genetics website at
    http://www.seattlegenetics.com/ in the Investors and News section

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and
commercialization of monoclonal antibody-based therapies for the treatment of
cancer. The U.S. Food and Drug Administration granted accelerated approval of
ADCETRIS in August 2011 for two indications. ADCETRIS is being developed in
collaboration with Millennium: The Takeda Oncology Company. In addition,
Seattle Genetics has three other clinical-stage ADC programs: SGN-75, ASG-5ME
and ASG-22ME. Seattle Genetics has collaborations for its ADC technology with
a number of leading biotechnology and pharmaceutical companies, including
Abbott, Agensys (an affiliate of Astellas), Bayer, Celldex Therapeutics,
Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics,
as well as ADC co-development agreements with Agensys and Genmab. More
information can be found at www.seattlegenetics.com.

Contact:

Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com
 
Press spacebar to pause and continue. Press esc to stop.